Biotechnology News

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with...

AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary...

Zurich, Switzerland, Sept. 04, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today...

Instinct Bio (Nasdaq: BIOT) updates on its Jakarta GENRÊVER CLINIC site, subscription tiers, and cosmetic product candidates with INVITRX and PARVA.

LONDRES, 04 sept. 2026 (GLOBE NEWSWIRE) -- Tangram Therapeutics (« Tangram »), société spécialisée dans le développement de médicaments innovants fondés sur l’ARNi visant à améliorer de manière...

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Tangram Therapeutics („Tangram“), ein Unternehmen, das sich der Entwicklung bahnbrechender RNAi-Medikamente zum Wohle der Patienten verschrieben hat, hat...

4 September 2026 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces that it will receive a $13 million milestone payment from AstraZeneca [LON: AZN], triggered...

COPENHAGEN, Denmark, September 4, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 285,900 as a consequence of employees’...

KØBENHAVN, Danmark, 4. september 2026 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har forhøjet sin aktiekapital med nominelt DKK 285.900 som følge af medarbejderes udnyttelse af...

–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with...